(1 H, m, 3ꢀ-H), 5.42 (1 H, d, J 4.60, 3ꢀ-OH), 5.65 (1 H, s, 5-H), 6.14
(1 H, t, J 5.31, 1ꢀ-H), 6.87–7.38 (m, H–arom), 8.53 (1 H, s, 4-H).
(1 H-arom, d, J 8.60), 8.31 (1 H-arom, s, C CH), 8.55 (1 H-arom,
s), 8.67 (1 H, s, 4-H), 10.8 (1 H, s, OH). (Found: ESI-HR-MS:
558.16 ([M + Na])+, C26H25N5O8; requires 535.17).
=
3-[2-Deoxy-5-O-(4,4ꢀ-dimethoxytriphenylmethyl)-b-D-erythro-
pentofuranosyl]-6-(hexyl)-furo[2,3-d]pyrimidin-3H-2-one
(12).
Preparation of the conjugate 31 from nucleoside 3 and 3-azido-7-
hydroxycoumarin (5)
As described above with compound 11 (400 mg, 0.62 mmol),
MeOH–Et3N, 7:3 (30 ml) and CuI (24 mg, 0.126 mmol).
Purification by FC (silica gel, column 15 × 3 cm, CH2Cl2–acetone
7:3) gave a colorless foam of 12 (348 mg, 87%). (Found: C,
71.35; H, 6.61; N, 4.36%. C38H42N2O7 requires C 71.45; H, 6.63;
N, 4.39%); TLC (silica gel, CH2Cl2–MeOH, 9:1): Rf 0.67; kmax
(MeOH)/nm 233 (e/dm3 mol−1 cm−1 27 000), 275 (3 000), 334
(5 400); dH (250.13 MHz; [d6]DMSO; Me4Si) 0.86 (3 H, CH3),
1.15–1.54 (8 H, m, CH2), 2.11 (2 H, m, 2ꢀ-H), 2.44 (2 H, m, CH2),
3.11 (2 H, m, 5ꢀ-H), 3.73 (6 H, s, 2 × OCH3), 4.0 (1 H, m, 4ꢀ-H),
4.39 (1 H, m, 3ꢀ-H), 5.42 (1 H, d, J 3.56, 3ꢀ-OH), 5.63 (1 H, s,
5-H), 6.14 (1 H, t, J 5.31, 1ꢀ-H), 6.87–7.36 (m, H–arom), 8.55
(1H, s, 4-H).
As described for 30 a solution of 3 (80 mg, 0.24 mmol), 3-azido-7-
hydroxycoumarin (5; 57 mg, 0.28 mmol) in THF–H2O–t-BuOH,
3:1:1 (4 ml) was stirred at r.t. for 30 h with 1 M aqueous sodium
ascorbate (210 ll, 0.21 mmol) and copper(II) sulfate pentahydrate
(173 ll, 0.052 mmol of a 7.5% stock solution in water). The solvent
was evaporated and applied to FC (silica gel, column 10 × 3 cm,
CH2Cl2–MeOH 85:15) to afford compound 31 (110 mg, 85%) as a
yellowish solid. TLC (silica gel, CH2Cl2–MeOH, 88:12): Rf 0.52.
kmax (MeOH)/nm 220 (e/dm3 mol−1 cm−1 25 000), 346 (13 000);
dH (300.15 MHz; [d6]DMSO; Me4Si) 1.70 (4 H, m, 2 × CH2), 2.03
(1 H, m, 2ꢀ-Ha), 2.30 (1 H, m, 2ꢀ-Hb), 2.58–2.74 (4 H, m, 2 ×
CH2), 3.62 (2 H, m, 5ꢀ-H), 3.87 (1 H, m, 4ꢀ-H), 4.22 (1 H, m, 3ꢀ-
H), 5.10 (1 H, 5ꢀ-OH), 5.25 (1 H, 3ꢀ-OH), 6.0 (1 H, s, 5-H), 6.24
(1 H, t, J 6.2, 1ꢀ-H), 6.84 (1 H-arom, d), 6.88–6.92 (1 H-arom, dd, J
3-[2-Deoxy-5-O-(4,4ꢀ -dimethoxytriphenylmethyl)-b-D-erythro-
pentofuranosyl]-6-(hexynyl)-furo[2,3-d]pyrimidin-3H-2-one-3ꢀ-(2-
cyanoethyl-N,N-diisopropylphosphoramidite (10). A stirred solu-
tion of 9 (170 mg, 0.27 mmol) in anhydrous CH2Cl2 (5 ml) was pre-
flushed with argon and treated with (i-Pr)2EtN (93 ll, 0.54 mmol)
followed by (2-cyanoethyl)diisopropylphosphoramidochloridite
(118 ll, 0.54 mmol). After stirring for 45 min at r.t. the solution
was diluted with CH2Cl2 (30 ml) and extracted with 5% aqueous
NaHCO3 solution (20 ml). The organic layer was dried (Na2SO4),
filtered and evaporated. FC (silica gel, column 10 × 3 cm, CH2Cl2–
acetone, 9:1) gave colorless foam of 10 (140 mg, 63%). TLC (silica
gel, CH2Cl2–acetone, 95:5): Rf 0.60. 31P NMR (CDCl3): 150.12,
149.74.
=
8.41), 7.74 (1 H-arom, d, J 8.70), 8.31 (1 H-arom, s, C CH), 8.49
(1 H, s, 4-H), 8.55 (1 H-arom, s), 10.9 (1 H, s, OH), 11.1 (1 H, s,
NH). (Found: ESI-HR-MS: 557.18 ([M + Na])+, C26H26N6O7;
requires 534.19).
Preparation of the conjugate 32 from nucleoside 6 and 3-azido-7-
hydroxycoumarin (5)
As described for 30 with 6 (100 mg, 0.30 mmol), 3-azido-7-
hydroxycoumarin (5; 74 mg, 0.36 mmol) in THF–H2O–t-BuOH,
3:1:1 (4 ml) was stirred at r.t for 10 h with 1 M aqueous sodium
ascorbate (300 ll, 0.30 mmol), copper(II) sulfate pentahydrate
(260 ll, 0.078 mmol of a 7.5% stock solution in water). The solvent
was evaporated and applied to FC (silica gel, column 10 × 3 cm,
CH2Cl2–MeOH 90:10) to afford compound 32 (130 mg, 81%) as
a yellowish solid. TLC (silica gel, CH2Cl2–MeOH, 9:1): Rf 0.30.
kmax (MeOH)/nm 297 (e/dm3 mol−1 cm−1 13 000), 346 (17 000); dH
(300.15 MHz; [d6]DMSO; Me4Si) 1.60–1.80 (4 H, m, 2 × CH2),
2.11 (2 H, m, 2ꢀ-H), 2.42 (2 H, m, CH2), 2.77 (2 H, m, CH2), 3.48
(2 H, m, 5ꢀ-H), 3.78 (1 H, m, 4ꢀ-H), 4.22 (1 H, m, 3ꢀ-H), 5.10 (1
H, 5ꢀ-OH), 5.23 (1 H, 3ꢀ-OH), 6.10 (1 H, t, J 6.45, 1ꢀ-H), 6.84 (1
H-arom, d), 6.88–6.92 (1 H-arom, dd, J 8.58), 7.74 (1 H-arom,
3-[2-Deoxy-5-O-(4,4ꢀ-dimethoxytriphenylmethyl)-b-D-erythro-
pentofuranosyl]-6-(hexyl)-furo[2,3-d]pyrimidin-3H-2-one
3ꢀ-(2-
cyanoethyl-N,N-diisopropylphosphor-amidite (13). As described
for 10, with 12 (200 mg, 0.31 mmol), (i-Pr)2EtN (100 ll, 0.58
mmol) and 2-cyanoethyl-diisopropylphosphoramidochloridite
(94 ll, 0.43 mmol). FC (silica gel, column 10 × 3 cm, CH2Cl2–
acetone 95:5) afforded 13 as a colorless foam (160 mg, 61%).
TLC (silica gel, CH2Cl2–acetone 9:1): Rf 0.70. 31P NMR (CDCl3):
150.88, 150.07.
Preparation of the conjugate 30 from nucleoside 7 and 3-azido-7-
hydroxycoumarin (5)
=
d, J 8.70), 8. 12 (1 H, s, 4-H), 8.31 (1 H-arom, s, C CH), 8.55
(1 H-arom, s), 10.9 (1 H, s, OH), 11.5 (1 H, s, NH). (Found:
To a solution of compound 7 (120 mg, 0.36 mmol) and 3-azido-7-
hydroxycoumarin (5; 86.5 mg, 0.43 mmol) in THF–H2O–t-BuOH,
3:1:1, (4 ml), was added sodium ascorbate (312 ll, 0.31 mmol) of a
freshly prepared 1 M solution in water, followed by the addition of
copper(II) sulfate pentahydrate 7.5% in water (260 ll, 0.078 mmol).
The emulsion was stirred for 24 h at r.t. evaporated, and applied to
FC (silica gel, column 10 × 3 cm, CH2Cl2–MeOH, 88:12). From
the main zone compound 30 (158 mg, 82%) was isolated as a
yellowish solid. TLC (silica gel, CH2Cl2–MeOH, 9:1): Rf 0.41. kmax
(MeOH)/nm 342 (e/dm3 mol−1 cm−1 22 000); dH (250.13 MHz;
[d6]DMSO; Me4Si) 1.70 (4 H, m, 2 × CH2), 2.06 (1 H, m, 2ꢀ-Ha),
2.39 (1 H, m, 2ꢀ-Hb), 2.74 (4 H, m, 2 × CH2), 3.63 (2 H, m, 5ꢀ-
H), 3.89 (1 H, m, 4ꢀ-H), 4.22 (1 H, m, 3ꢀ-H), 5.12 (1 H, 5ꢀ-OH),
5.28 (1 H, 3ꢀ-OH), 6.16 (1 H, t, J 6.12, 1ꢀ-H), 6.45 (1 H, s, 5-H),
6.84 (1 H-arom, d, J 2.05), 6.87–6.92 (1 H-arom, dd, J 8.50), 7.74
ESI-HR-MS: 558.16 ([M + Na])+, C26H25N5O8; requires 535.17).
Preparation of the conjugate 33 from nucleoside 4 and 3-azido-7-
hydroxycoumarin (5)
Compound 33 was synthesised from 4 (60 mg, 0.18 mmol)
according to the above method. Compound 33 (59 mg, 61%)
was isolated from the main zone as a yellowish solid. TLC
(silica gel, CH2Cl2–MeOH, 9:1): Rf 0.15. kmax (MeOH)/nm 345
(e/dm3 mol−1 cm−1 9 500); dH (300.15 MHz; [d6]DMSO; Me4Si)
1.61–1.77 (4 H, m, 2 × CH2), 1.98–2.10 (2 H, m, 2ꢀ-H), 2.46 (2 H,
m, CH2), 2.75 (2 H, m, CH2), 3.56 (2 H, m, 5ꢀ-H), 3.78 (1 H, m, 4ꢀ-
H), 4.20 (1 H, m, 3ꢀ-H), 5.06 (1 H, 5ꢀ-OH), 5.20 (1 H, 3ꢀ-OH), 6.10
(1 H, t, J 6.18, 1ꢀ-H), 6.84 (1 H-arom, d), 6.74 (1 H, s, NHa), 6.85
(1 H-arom, d), 6.89–6.92 (1 H-arom, dd, J 8.46), 7.71 (1 H, s, NHb),
1686 | Org. Biomol. Chem., 2008, 6, 1674–1687
This journal is
The Royal Society of Chemistry 2008
©